Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VLA-1601 by Valneva for Zika Virus Infections: Likelihood of Approval
VLA-1601 is under clinical development by Valneva and currently in Phase I for Zika Virus Infections. According to GlobalData, Phase...